Cartesian Therapeutics, Inc.
RNAC
$6.65
-$0.06-0.89%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -97.72% | -98.10% | 31.91% | 49.64% | -62.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.72% | -98.10% | 31.91% | 49.64% | -62.40% |
| Cost of Revenue | -4.07% | -18.70% | -49.82% | -64.37% | -75.68% |
| Gross Profit | -233.17% | -202.59% | 146.77% | 139.13% | 78.67% |
| SG&A Expenses | -21.71% | -24.78% | -23.52% | -15.03% | -5.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.08% | -9.78% | -16.35% | -25.87% | -43.81% |
| Operating Income | -106.25% | -122.31% | 34.58% | 52.26% | -34.55% |
| Income Before Tax | 81.92% | 85.53% | 86.12% | 67.69% | -12,487.26% |
| Income Tax Expenses | 101.51% | 101.51% | 101.51% | 101.51% | -3,019.87% |
| Earnings from Continuing Operations | 80.40% | 84.21% | 84.97% | 64.76% | -16,364.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.40% | 84.21% | 84.97% | 64.76% | -16,364.63% |
| EBIT | -106.25% | -122.31% | 34.58% | 52.26% | -34.55% |
| EBITDA | -103.97% | -120.47% | 36.93% | 53.28% | -39.63% |
| EPS Basic | 96.36% | 96.89% | 97.17% | 78.16% | -520.29% |
| Normalized Basic EPS | 91.65% | 92.83% | 97.07% | 91.12% | -317.30% |
| EPS Diluted | 96.31% | 96.85% | 97.09% | 78.06% | -520.48% |
| Normalized Diluted EPS | 91.70% | 92.87% | 96.97% | 91.02% | -317.79% |
| Average Basic Shares Outstanding | 111.25% | 203.07% | 326.63% | 233.80% | 217.83% |
| Average Diluted Shares Outstanding | 107.67% | 194.85% | 331.72% | 238.96% | 224.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |